More in

Fresenius Kabi’s Ivenix infusion system delivers critical medication

The Metrodora Institute, an integrated, multidisciplinary medical and research center that treats neuroimmune axis disorders, is using Fresenius Kabi’s Ivenix infusion system for its infusion medicine needs.

The patented pumping technology in the Ivenix infusion system delivers critical medications with flow that is continuously measured and controlled to help optimize safety. The pump achieves accurate medication delivery unaffected by external conditions such as bag height, back pressure, and fluid viscosity, and it helps to prevent uncontrolled flow.

The Ivenix large-volume pump includes a large, smartphone-like touchscreen that allows clinicians to automatically program, review and accept medication orders on the pump. The built-in integration engine supports secure interoperability with leading electronic medical records (EMR) systems and includes tools to automate testing, reducing implementation timelines and resources required to synchronize drug libraries with EMR formularies.

The Ivenix platform also facilitates enterprise-wide, centralized management of the entire pump fleet. This allows for oversight of the infusion pump fleet, including device utilization, location awareness, proactive maintenance, user management, and remote software and security updates—without wasting time hunting and gathering devices.

“The Ivenix system’s adaptability makes it incredibly easy to use in clinical trials and in providing necessary infusion therapies,” said Shannon Flitton, RN, MSN, clinical operations manager at Metrodora Institute. “The modern system provides our nursing team with a safe, more efficient medication administration process, allowing us to focus on delivering the precise care patients need.”

Eric Sato, vice president of marketing at Fresenius Kabi, said: ”Simplicity of operation, intelligence, and reliability coupled with adherence to FDA infusion pump guidelines all make Ivenix an ideal choice for advanced medical care.”